Anticoagulation for heart failure: selecting the best therapy

References

• Young JB. The global epidemiology of heart failure. Med. Clin. North Am.88(5), 1135–1143 (2004).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation119(3), 480–486 (2009).
   PubMed Web of Science ®Google Scholar
• Yan AT, Yan RT, Liu PP. Narrative review: pharmacotherapy for chronic heart failure: evidence from recent clinical trials. Ann. Intern. Med.142(2), 132–145 (2005).
   PubMed Web of Science ®Google Scholar
• Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation112(12), E154–E235 (2005).
   PubMed Web of Science ®Google Scholar
• Garg R, Yusuf S; Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA273(18), 1450–1456 (1995).
   PubMed Web of Science ®Google Scholar
• Mielniczuk L, Stevenson LW. Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers in the management of congestive heart failure patients: what have we learned from recent clinical trials? Curr. Opin. Cardiol.20(4), 250–255 (2005).
   PubMed Web of Science ®Google Scholar
• Goldstein S, Hjalmarson A. Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Circulation98(Suppl. I), 364 (1998).
   Google Scholar
• Pitt B, Zannad F, Remme WJ; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med.41(10), 709–717 (1999).
   Google Scholar
• Turer AT, Rao SV. Device therapy in the management of congestive heart failure. Cardiol. Rev.13(3), 130–138 (2005).
   Google Scholar
• Polanczyk CA, Rohde LE, Dec GW, DiSalvo T. Ten-year trends in hospital care for congestive heart failure: improved outcomes and increased use of resources. Arch. Intern. Med.160(3), 325–332 (2000).
   PubMedGoogle Scholar
• Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J. Am. Coll. Cardiol.29(5), 1074–1080 (1997).
   PubMed Web of Science ®Google Scholar
• Adams HP Jr, Bendixen BH, Kappelle LJ. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke24(1), 35–41 (1993).
   PubMed Web of Science ®Google Scholar
• Kalaria VG, Passannante MR, Shah T, Modi K, Weisse AB. Effect of mitral regurgitation on left ventricular thrombus formation in dilated cardiomyopathy. Am. Heart J.135(2 Pt 1), 215–220 (1998).
   Google Scholar
• Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow’s triad revisited. J. Am. Coll. Cardiol.33(5), 1424–1426 (1999).
   PubMed Web of Science ®Google Scholar
• Tikiz H, Balbay Y, Atak R, Terzi T, Genc Y, Kutuk E. The effect of thrombolytic therapy on left ventricular aneurysm formation in acute myocardial infarction: relationship to successful reperfusion and vessel patency. Clin. Cardiol.24(10), 656–662 (2001).
   Google Scholar
• Reeder GS, Lengyel M, Tajik AJ, Seward JB, Smith HC, Danielson GK. Mural thrombus in left ventricular aneurysm: incidence, role of angiography, and relation between anticoagulation and embolization. Mayo Clin. Proc.56(2), 77–81 (1981).
   PubMed Web of Science ®Google Scholar
• Kerkhoff GO, Hofs C, Roer N et al. Images in cardiovascular medicine. Left ventricular pseudoaneurysm: clinical role of cardiovascular magnetic resonance imaging. Circulation109(20), E222–E223 (2004).
   Google Scholar
• Loh E, Sutton MS, Wun CC et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N. Engl. J. Med.336(4), 251–257 (1997).
   PubMed Web of Science ®Google Scholar
• Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology54(2), 288–294 (2000).
   PubMed Web of Science ®Google Scholar
• Gorelick PB, Sacco RL, Smith DB et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA281(12), 1112–1120 (1999).
   PubMed Web of Science ®Google Scholar
• Massie BM, Krol WF, Ammon SE et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J. Card. Fail.10(2), 101–112 (2004).
   Google Scholar
• Siachos T, Vanbakel A, Feldman DS, Uber W, Simpson KN, Pereira NL. Silent strokes in patients with heart failure. J. Card. Fail.11(7), 485–489 (2005).
   PubMed Web of Science ®Google Scholar
• Freudenberger RS, Massie BM. Silent cerebral infarction in heart failure: vascular or thromboembolic? J. Card. Fail.11(7), 490–491 (2005).
   Google Scholar
• Sharma ND, McCullough PA, Philbin EF, Weaver WD. Left ventricular thrombus and subsequent thromboembolism in patients with severe systolic dysfunction. Chest117(2), 314–320 (2000).
   PubMed Web of Science ®Google Scholar
• Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology44(4), 626–634 (1994).
   PubMed Web of Science ®Google Scholar
• Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology50(1), 208–216 (1998).
   PubMed Web of Science ®Google Scholar
• Cogo A, Bernardi E, Prandoni P et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch. Intern. Med.154(2), 164–168 (1994).
   Google Scholar
• Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch. Intern. Med.160(22), 3415–3420 (2000).
   PubMed Web of Science ®Google Scholar
• Ageno W, Squizzato A, Ambrosini F et al. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica87(7), 746–750 (2002).
   Google Scholar
• Monreal M, Munoz-Torrero JF, Naraine VS et al. Pulmonary embolism in patients with chronic obstructive pulmonary disease or congestive heart failure. Am. J. Med.119(10), 851–858 (2006).
   Google Scholar
• Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest126(3 Suppl.), S338–S400 (2004).
   PubMedGoogle Scholar
• Abraham WT, Fisher WG, Smith AL et al. Cardiac resynchronization in chronic heart failure. N. Engl. J. Med.346, 1845–1853 (2002).
   PubMed Web of Science ®Google Scholar
• Cleland JG, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med.352(15), 1539–1549 (2005).
   PubMed Web of Science ®Google Scholar
• Pullicino P, Thompson JL, Barton B, Levin B, Graham S, Freudenberger RS. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J. Card. Fail.12(1), 39–46 (2006).
   Google Scholar
• Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N. Engl. J. Med.323(3), 147–152 (1990).
   PubMed Web of Science ®Google Scholar
• Liao JK. Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer? Circulation115(12), 1615–1621 (2007).
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet348(9038), 1329–1339 (1996).
   PubMed Web of Science ®Google Scholar
• Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet362(9397), 1691–1698 (2003).
   PubMed Web of Science ®Google Scholar
• Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet343(8896), 499–503 (1994).
   PubMed Web of Science ®Google Scholar
• Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN; The V-HeFT VA Cooperative Studies Group. Incidence of thromboembolic events in congestive heart failure. Circulation87(6 Suppl.), VI94–VI101 (1993).
   Google Scholar
• Report of the Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet82(8202), 989–994 (1980).
   Google Scholar
• Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J. Am. Coll. Cardiol.31(4), 749–753 (1998).
   PubMed Web of Science ®Google Scholar
• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med.316(23), 1429–1435 (1987).
   PubMed Web of Science ®Google Scholar
• de Boer RA, Hillege HL, Tjeerdsma G, Verheugt FW, van Veldhuisen DJ. Both antiplatelet and anticoagulant therapy may favorably affect outcome in patients with advanced heart failure. A retrospective analysis of the PRIME-II trial. Thromb. Res.116(4), 279–285 (2005).
   Google Scholar
• Cleland JG, Findlay I, Jafri S et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am. Heart J.148(1), 157–164 (2004).
   PubMed Web of Science ®Google Scholar
• Kyrle PA, Korninger C, Gossinger Het al. Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thromb. Haemost.54(2), 521–523 (1985).
   PubMed Web of Science ®Google Scholar
• Hart RG, Halperin JL. Atrial fibrillation and stroke. Revisiting the dilemmas. Stroke25(7), 1337–1341 (1994).
   Google Scholar
• Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med.154(13), 1449–1457 (1994).
   PubMed Web of Science ®Google Scholar
• Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N. Engl. J. Med.335(8), 540–546 (1996).
   PubMed Web of Science ®Google Scholar
• Harvey WP, Finch CA. Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. N. Engl. J. Med.242(6), 208–211 (1950).
   PubMed Web of Science ®Google Scholar
• Griffith GC, Stragnell R, Levinson DC, Moore FJ, Ware AG. A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann. Intern. Med.37(5), 867–887 (1952).
   Google Scholar
• Anderson GM, Hull E. The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. Am. Heart J.39(5), 697–702 (1950).
   PubMed Web of Science ®Google Scholar
• Lip GY, Gibbs CR. Anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. Q. J. Med.95(7), 451–459 (2002).
   Google Scholar
• Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med.325(5), 303–310 (1991).
   PubMed Web of Science ®Google Scholar
• Lip GY, Gibbs CR. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. Q. J. Med.95(7), 461–468 (2002).
   Google Scholar
• Falk RH, Pollak A, Tandon PK, Packer M. The effect of warfarin on prevalence of stroke in patients with severe heart failure. J. Am. Coll. Cardiol. 21:218A (1993).
   Google Scholar
• Massie BM, Collins JF, Ammon SE et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation119(12), 1616–1624 (2009).
   PubMed Web of Science ®Google Scholar
• Cleland JG, Ghosh J, Freemantle N et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur. J. Heart Fail.6(4), 501–508 (2004).
   PubMed Web of Science ®Google Scholar
• Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J. Am. Coll. Cardiol.31(2), 419–425 (1998).
   PubMed Web of Science ®Google Scholar
• Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am. J. Cardiol.79(2), 115–119 (1997).
   PubMed Web of Science ®Google Scholar
• Leor J, Reicher-Reiss H, Goldbourt U et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. J. Am. Coll. Cardiol.33(7), 1920–1925 (1999).
   PubMed Web of Science ®Google Scholar
• Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation113(10), E409–E449 (2006).
   PubMed Web of Science ®Google Scholar
• Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N. Engl. J. Med.347(13), 969–974 (2002).
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA285(22), 2864–2870 (2001).
   PubMed Web of Science ®Google Scholar
• van Veldhuisen DJ, Aass H, El Allaf D et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. Eur. J. Heart Fail.8(5), 539–546 (2006).
   PubMed Web of Science ®Google Scholar
• Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA289(2), 194–202 (2003).
   PubMed Web of Science ®Google Scholar
• Olsson LG, Swedberg K, Ducharme A et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J. Am. Coll. Cardiol.47(10), 1997–2004 (2006).
   PubMed Web of Science ®Google Scholar
• Parkash R, Maisel WH, Toca FM, Stevenson WG. Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved. Am. Heart J.150(4), 701–706 (2005).
   PubMedGoogle Scholar
• Sherman DG, Dyken ML, Fisher M, Harrison MJ, Hart RG. Antithrombotic therapy for cerebrovascular disorders. Chest95(2 Suppl.), S140–S155 (1989).
   PubMed Web of Science ®Google Scholar
• Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation103(13), 1746–1751 (2001).
   PubMed Web of Science ®Google Scholar
• Cugno M, Mari D, Meroni PL et al. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. Br. J. Haematol.126(1), 85–92 (2004).
   PubMed Web of Science ®Google Scholar
• Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J. Am. Coll. Cardiol.32(3), 695–703 (1998).
   PubMed Web of Science ®Google Scholar